408 related articles for article (PubMed ID: 20427160)
1. Doxorubicin-incorporated nanoparticles composed of poly(ethylene glycol)-grafted carboxymethyl chitosan and antitumor activity against glioma cells in vitro.
Jeong YI; Jin SG; Kim IY; Pei J; Wen M; Jung TY; Moon KS; Jung S
Colloids Surf B Biointerfaces; 2010 Aug; 79(1):149-55. PubMed ID: 20427160
[TBL] [Abstract][Full Text] [Related]
2. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy.
Ko J; Park K; Kim YS; Kim MS; Han JK; Kim K; Park RW; Kim IS; Song HK; Lee DS; Kwon IC
J Control Release; 2007 Nov; 123(2):109-15. PubMed ID: 17894942
[TBL] [Abstract][Full Text] [Related]
3. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
[TBL] [Abstract][Full Text] [Related]
4. Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery.
Gou M; Zheng X; Men K; Zhang J; Zheng L; Wang X; Luo F; Zhao Y; Zhao X; Wei Y; Qian Z
J Phys Chem B; 2009 Oct; 113(39):12928-33. PubMed ID: 19736995
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
[TBL] [Abstract][Full Text] [Related]
6. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin.
Zhang J; Chen XG; Li YY; Liu CS
Nanomedicine; 2007 Dec; 3(4):258-65. PubMed ID: 17962086
[TBL] [Abstract][Full Text] [Related]
7. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles.
Hu FQ; Liu LN; Du YZ; Yuan H
Biomaterials; 2009 Dec; 30(36):6955-63. PubMed ID: 19782395
[TBL] [Abstract][Full Text] [Related]
9. Effect of molecular weight on the oleoyl-chitosan nanoparticles as carriers for doxorubicin.
Zhang J; Chen XG; Sun GZ; Huang L; Cheng XJ
Colloids Surf B Biointerfaces; 2010 Jun; 77(2):125-30. PubMed ID: 20172698
[TBL] [Abstract][Full Text] [Related]
10. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
11. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery.
Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
Biomaterials; 2009 Oct; 30(29):5757-66. PubMed ID: 19643472
[TBL] [Abstract][Full Text] [Related]
12. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
[TBL] [Abstract][Full Text] [Related]
13. pH-sensitive chitosan-derived nanoparticles as doxorubicin carriers for effective anti-tumor activity: preparation and in vitro evaluation.
Jin YH; Hu HY; Qiao MX; Zhu J; Qi JW; Hu CJ; Zhang Q; Chen DW
Colloids Surf B Biointerfaces; 2012 Jun; 94():184-91. PubMed ID: 22405470
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate-incorporated polymeric nanoparticles of methoxy poly(ethylene glycol)-grafted chitosan.
Seo DH; Jeong YI; Kim DG; Jang MJ; Jang MK; Nah JW
Colloids Surf B Biointerfaces; 2009 Mar; 69(2):157-63. PubMed ID: 19135342
[TBL] [Abstract][Full Text] [Related]
15. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
16. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
17. Novel method of doxorubicin-SPION reversible association for magnetic drug targeting.
Munnier E; Cohen-Jonathan S; Linassier C; Douziech-Eyrolles L; Marchais H; Soucé M; Hervé K; Dubois P; Chourpa I
Int J Pharm; 2008 Nov; 363(1-2):170-6. PubMed ID: 18687392
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin release from self-assembled nanoparticles of deoxycholic acid-conjugated dextran.
Jeong YI; Chung KD; Choi KC
Arch Pharm Res; 2011 Jan; 34(1):159-67. PubMed ID: 21468928
[TBL] [Abstract][Full Text] [Related]
19. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
20. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM
Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
